FDA staff concentration on Onyx cancer drug’s side effects

<p>WASHINGTON (Reuters) – U.S. drug reviewers pronounced a critical heart, lung and liver <span>side effects</span> of <span>Onyx Pharmaceuticals Inc</span>‘s carfilzomib drug might transcend a drug’s advantages for patients with a form of blood cancer.</p>
<p> The <span>Food and Drug Administration staff</span> pronounced about 22 percent of people holding a drug during a pivotal <span>clinical trial</span> responded to a treatment, and many had critical side effects, definition carfilzomib might not be improved than comparison treatments for <span>multiple myeloma</span>.</p>
<p> “<span>FDA</span> is really endangered with a critical toxicities, including deaths that are compared with a use of this agent,” a reviewers pronounced in papers posted online on Monday, adding that it was not transparent either a drug caused a side effects.</p>
<p> ...